Christoph Zeyen

Christoph Zeyen

Auto-generated profile, based on publicly available information

Christoph Zeyen

Division of Evidence‐Based Medicine (dEBM) Department of Dermatology Venereology and Allergology Charité – Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2026 in Allergy
Verified
Journal Article
Open access
Torsten ZuberbierTorsten Zuberbier
Torsten Zuberbier
ZAZainab AbdulHameed Ansari
Zainab AbdulHameed Ansari
ALAmir H. Abdul Latiff
Amir H. Abdul Latiff
MAM. M. Abuzakouk
M. M. Abuzakouk
MJMaria Socorro Agcaoili‐De Jesus
Maria Socorro Agcaoili‐De Jesus
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA 2 LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.

12 October 2023 in Allergy
Verified
Journal Article
Open access
Ralph MösgesRalph Mösges
Ralph Mösges
CZChristoph Zeyen
Christoph Zeyen
EREsther Raskopf
Esther Raskopf
CACengizhan Acikel
Cengizhan Acikel
HSHacer Sahin
Hacer Sahin
MCMiguel Casanovas
Miguel Casanovas
Background: There is still great need to develop new strategies to improve the efficacy of allergen immunotherapies with optimal safety standards for patients. A new promising approach is to couple allergoids to mannan. The objective of this phase IIa/IIb study was to identify the optimal dose of mannan-conjugated birch pollen allergoids for the short-course treatment of birch pollen-induced allergic rhinoconjunctivitis.Methods: For this prospective, randomized, double-blind, placebo-controlled, dose-finding study, 246 birch pollen-allergic adults received 0.5 mL placebo or 1000, 3000 or 10,000 mTU/mL of mannan-conjugated birch pollen allergoids at five pre-seasonal visits. Efficacy was assessed by comparing allergic rhinoconjunctivitis symptoms and use of anti-allergic medication during the peak of the birch pollen season 2020. Immunologic, tolerability and safety effects were also analysed.Results: The highest dose of mannan-conjugated birch pollen allergoids reduced the combined symptom and medication score during the peak birch pollen season by a median of 24.7% compared to placebo. The production of Bet v 1 specific IgG4 significantly increased in a dose-dependent manner (3.6- and 4.5-fold) in the 3000 and 10,000 mTU/mL groups. The Bet v 1 specific IgE/IgG4 ratio was also strongly reduced (up to -70%). No fatalities nor serious adverse events were reported, and no adrenaline was used. In total, four systemic reactions occurred (two grade I and two grade II).Conclusion: All doses of mannan-conjugated birch pollen allergoids can be considered as safe. Since the application of 10,000 mTU/mL resulted in the highest efficacy, this dose qualifies for further investigation.

15 March 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
CZChristoph Zeyen
Christoph Zeyen
MKMaria Kinberger
Maria Kinberger
HKHelene Kriedemann
Helene Kriedemann
FPFrieder Pfäfflin
Frieder Pfäfflin
PTPinkus Tober-Lau
Pinkus Tober-Lau
RWRicardo Niklas Werner
Ricardo Niklas Werner
Background: Cases of mpox have been reported worldwide since May 2022. Limited knowledge exists regarding the long-term course of this disease. To assess sequelae in terms of scarring and quality of life (QoL) in mpox patients 4–6 months after initial infection. Methods: Prospective observational study on clinical characteristics and symptoms of patients with polymerase chain reaction (PCR)-confirmed mpox, including both outpatients and inpatients. Follow-up visits were conducted at 4–6 months, assessing the Patient and Observer Scar Assessment Scale (POSAS), the Dermatology Life Quality Index (DLQI) and sexual impairment, using a numeric rating scale (NRS) from 0 to 10. Results: Forty-three patients, age range 19–64 years, 41 men (all identifying as MSM) and 2 women, were included. Upon diagnosis, skin or mucosal lesions were present in 93.0% of cases, with 73.3% reporting pain (median intensity: 8, Q1-Q3: 6–10). Anal involvement resulted in a significantly higher frequency of pain than genital lesions (RR: 3.60, 95%-CI: 1.48–8.74). Inpatient treatment due to pain, superinfection, abscess or other indications was required in 20 patients (46.5%). After 4–6 months, most patients did not have significant limitations, scars or pain. However, compared to patients without such complications, patients with superinfection or abscess during the acute phase had significantly more extensive scar formation (median PSAS: 24.0 vs. 11.0, p = 0.039) and experienced a significantly greater impairment of their QoL (median DLQI: 2.0 vs. 0.0, p = 0.036) and sexuality (median NRS: 5.0 vs. 0.0, p = 0.017). Conclusion: We observed a wide range of clinical mpox manifestations, with some patients experiencing significant pain and requiring hospitalization. After 4–6 months, most patients recovered without significant sequelae, but those with abscesses or superinfections during the initial infection experienced a significant reduction in QoL and sexuality. Adequate treatment, including antiseptic and antibiotic therapy during the acute phase, may help prevent such complications, and hence, improve long-term outcomes.

14 January 2026 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
ANAlexander Nast
Alexander Nast
AAAndreas Altenburg
Andreas Altenburg
MAMatthias Augustin
Matthias Augustin
FBFrank Bachmann
Frank Bachmann
WBWolf‐Henning Boehncke
Wolf‐Henning Boehncke
CZChristoph Zeyen
Christoph Zeyen
Summary: This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies. The recommendations are based on the current Cochrane network meta‐analysis, the results of which are also summarized. When selecting systemic therapies for psoriasis vulgaris, the guideline emphasizes consideration of efficacy, safety, comorbidities, and individual patient factors. The decision framework is presented in the treatment options overview, and in this updated version, the possibility of first‐line therapy with biologics or novel targeted small molecules is more prominently highlighted. Standardized instruments for assessing disease severity, as well as patient‐centered treatment goals, are underscored. A Psoriasis Area and Severity Index (PASI) 75 response is defined as the minimum therapeutic target, while PASI 90 or an absolute PASI <2 are considered desirable goals. Since the last version, two newly approved agents, bimekizumab and deucravacitinib, have been incorporated, accompanied by specific usage recommendations. Among the established therapies, guidance on methotrexate has been extensively revised, particularly regarding administration, dosing, and monitoring. This guideline aims to provide clinicians with an evidence‐based framework for therapy selection and monitoring, while strengthening shared decision‐making with patients.

31 July 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
KKKonstanze Kämmerer
Konstanze Kämmerer
JHJulia Huynh
Julia Huynh
CDCornelia Deutsch
Cornelia Deutsch
SMStefanie May
Stefanie May
SUSertac Uyar
Sertac Uyar
RWRicardo Niklas Werner
Ricardo Niklas Werner
Summary: Background and Objectives: Sexually transmitted infections with Trichophyton mentagrophytes type VII (TMVII) have been reported in several countries. The aim of our study was to identify epidemiological and clinical features in order to improve prevention, diagnosis, and treatment. Patients and Methods: Patients with culture‐confirmed TMVII infection diagnosed between 2020 and 2024 at the Department of Dermatology, Charité – Universitätsmedizin Berlin, Germany, were included. Patient characteristics, clinical presentation, and treatment were assessed. Results: Fifty‐one patients were included (96.1% male; median age, 34 years), with 94.6% of male patients reporting male sex partners. Among 47 patients with known HIV status, 19.1% were living with HIV, while 71.1% of HIV‐negative patients reported using pre‐exposure prophylaxis (PrEP). Median time to diagnosis was 42.5 days (Q1–Q3: 29.25–73.5). Atypical morphologies, such as purulent or infiltrated subcutaneous lesions, occurred in 82.4%, and 96.1% had genital, perianal, or perioral manifestations. Median systemic treatment duration was 83.5 days (Q1–Q3: 57–110.25), with no significant differences by morphology ( p = 0.69) or HIV/PrEP status ( p = 0.88). Conclusions: TMVII infections often present with atypical morphology and should be considered in the differential diagnosis of genital, perianal, and perioral dermatoses, particularly among men with multiple male partners. Clinicians should anticipate prolonged treatment durations to achieve clearance and prevent recurrence.

5 February 2026 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
ANAlexander Nast
Alexander Nast
AAAndreas Altenburg
Andreas Altenburg
MAMatthias Augustin
Matthias Augustin
FBFrank Bachmann
Frank Bachmann
WBWolf‐Henning Boehncke
Wolf‐Henning Boehncke
CZChristoph Zeyen
Christoph Zeyen
Summary: The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon‐gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients with a history of malignancy and viral hepatitis.